SCHEMBL3034653

SCHEMBL3034653

CCCCC(CCC)OC=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSK P43235 7/20 0.47
TSHR P16473 3/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
PRKCA P17252 1/20 0.33
PRKCD Q05655 1/20 0.33
ACHE P22303 1/20 0.32
BACE1 P56817 1/20 0.32
ADH1B P00325 1/20 0.32
ADH1C P00326 1/20 0.32
ADH1A P07327 1/20 0.32
ADH4 P08319 1/20 0.32
ADH7 P40394 1/20 0.32
CA1 P00915 1/20 0.32
CA2 P00918 1/20 0.32
CYP3A4 P08684 2/20 0.32
ALDH1A1 P00352 1/20 0.32
FDPS P14324 1/20 0.32
DNM1 Q05193 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.31
TRPA1 O75762 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9407800 1.00 CTSK (0.47) CTSKTSHRSMN1; SMN2PRKCAPRKCD
SCHEMBL3034857 0.95 TSHR (0.44) CTSKTSHRSMN1; SMN2PRKCAPRKCD
SCHEMBL3007421 0.93 CTSK (0.42) CTSKTSHRSMN1; SMN2ADH1BADH1C
SCHEMBL18187977 0.91 ADH1B (0.42) CTSKTSHRADH1BADH1CADH1A
SCHEMBL276606 0.91 ADH1B (0.42) CTSKTSHRADH1BADH1CADH1A
SCHEMBL18188007 0.91 ADH1B (0.42) CTSKTSHRADH1BADH1CADH1A
SCHEMBL18187974 0.91 TSHR (0.41) CTSKTSHRSMN1; SMN2ADH1BADH1C
SCHEMBL3035044 0.91 CTSK (0.40) CTSKTSHRSMN1; SMN2PRKCAPRKCD
SCHEMBL18188040 0.89 ADH1B (0.44) CTSKTSHRSMN1; SMN2ADH1BADH1C
SCHEMBL18187973 0.89 ADH1B (0.44) CTSKTSHRSMN1; SMN2ADH1BADH1C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9580636-B2 Secondary esters, methods of making, and uses thereof CHEVRON PHILLIPS CHEMICAL COMPANY LP (US) 2017-02-28 US claimed
US-20160319178-A1 Secondary Esters, Methods of Making, and Uses Thereof CHEVRON PHILLIPS CHEMICAL COMPANY LP 2016-11-03 US claimed
WO-2016176243-A1 SECONDARY ESTERS, METHODS OF MAKING, AND USES THEREOF CHEVRON PHILLIPS CHEMICAL COMPANY LP (US) 2016-11-03 WO claimed
CN-111936457-B Enol ether pro-fragrances 弗门尼舍有限公司 2025-02-25 CN disclosed
CN-112028892-B Application of 4-amino-pyrrolotriazine derivative in preparation of anti-pulmonary fibrosis preparation 天津全和诚科技有限责任公司 2022-12-16 CN disclosed
CN-108212215-A The catalyst system closed for ethylene oligomerization and the method using its production ethylene low polymer 韩华道达尔有限公司 2018-06-29 CN disclosed
US-9580636-B2 Secondary esters, methods of making, and uses thereof CHEVRON PHILLIPS CHEMICAL COMPANY LP (US) 2017-02-28 US disclosed
US-20160319178-A1 Secondary Esters, Methods of Making, and Uses Thereof CHEVRON PHILLIPS CHEMICAL COMPANY LP 2016-11-03 US disclosed
WO-2016176243-A1 SECONDARY ESTERS, METHODS OF MAKING, AND USES THEREOF CHEVRON PHILLIPS CHEMICAL COMPANY LP (US) 2016-11-03 WO disclosed
US-20100216736-A2 2'-CYANOPYRIMIDINE NUCLEOSIDE COMPOUND TAIHO PHARMACEUTICAL CO., LTD. (JP) 2010-08-26 US disclosed
US-20100056466-A1 2'-Cyanopyrimidine Nucleoside Compound MATSUDA, AKIRA (JP) 2010-03-04 US disclosed
EP-2045256-A1 2'-CYANOPYRIMIDINE NUCLEOSIDE COMPOUND TAIHO PHARMACEUTICAL COMPANY, LIMITED (JP) 2009-04-08 EP disclosed
US-6503961-B1 Composition comprising urethane (meth)acrylate derived from polyester polyol or polycarbonate polyol, compound having ethylenically unsaturated group together with cyclic imide group, and optional additional unsaturated compound TOAGOSEI CO., LTD. (JP) 2003-01-07 US disclosed
US-5691319-A ANTICARCINOGENIC AGENTS SANKYO COMPANY, LIMITED (JP) 1997-11-25 US disclosed
EP-0536936-B1 Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and use SANKYO CO (JP) 1996-08-14 EP disclosed
EP-0536936-A1 Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and use Sankyo Company Limited (JP) 1993-04-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100216736-A2 2'-CYANOPYRIMIDINE NUCLEOSIDE COMPOUND NUDT1, DPYD, SLC29A1 CTSK 4594/4885TSHR 2498/4885SMN1; SMN2 1045/4885
US-20100056466-A1 2'-Cyanopyrimidine Nucleoside Compound NUDT1, DPYD, SLC29A1 CTSK 4594/4885TSHR 2498/4885SMN1; SMN2 1045/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.